Global Liver Institute Statement on the Passing of Dr. Stephen Harrison
The entire field of liver health has experienced an incredible loss. It is with great sadness that Global Liver Institute, our Liver Action Network members and the patient community express our deepest sorrow on the sudden passing of Dr Stephen Harrison. Our condolences and prayers are with Dr. Harrison’s family, friends and loved ones.
Addressing Disparities in Organ Transplantation: A Call for Equitable Healthcare
Organ transplantation has revolutionized modern medicine, offering a beacon of hope for individuals battling end-stage organ failure. At the same time, it is intricately entwined with legal and policy frameworks governing procurement, allocation, and ethical considerations. From national regulations to international collaborations, addressing healthcare disparities and combating systemic injustices are vital to providing equal access to lifesaving procedures.
Congress begins Fiscal Year 2025 appropriations process and the Administration approves new treatments improving the lives of liver disease patients.
After a brief weekend shutdown, Congress passed the FY 2024 appropriations bills and President Joe Biden signed the $1.2 trillion government funding package on March 23, 2024, closing the books on fiscal year (FY) 2024 appropriations.
Celebrating the benefits of drug repurposing for pediatric rare liver disease patients – Pediatric & Rare Liver Diseases News
Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).
GLI Celebrates US Treatment for NASH as Milestone for Liver Health – NASH News
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S.
This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development.